Search results for: 'data mitigation solutions q2 2026'

The global pharmaceutical market is projected to reach approximately $1.72 trillion in 2026, with large molecules driving most incremental growth while small molecules remain the sector’s cash flow base. The current growth cycle concentrates on cardiometabolic and oncology, led by GLP-1 platforms and antibody–drug conjugates (ADCs). Competitive adv...

The evolving IT landscape has played a transformative role in the field of life sciences, enabling a reliance on real-world evidence (RWE) solutions. With growing competition and the demand for precision in decision-making, pharmaceutical companies, healthcare providers, and technology organizations have realized the need for real-world data (RWD) ...

Europe’s life sciences sector is approaching a defining inflection point in 2026, as major regulatory and policy reforms converge to reshape pharma, diagnostics, life sciences IT, biotechnology, and the bioeconomy. Together, these frameworks open clear growth pathways across the value chain: the Clinical Trials Regulation (CTR) and European Health ...

The global biopharma patient access market is undergoing a structural shift as specialty medicines make downstream commercialization more complex and strategically important. Patient access is no longer limited to reimbursement support or hub services; it is becoming a commercialization control layer spanning authorization, affordability, therapy i...

The SCOPE Summit 2026, held in Orlando, Florida, from February 2 to 5, 2026, highlighted the dominance of small- to mid-segment companies and specialized CROs focusing on specific therapy areas or aspects of clinical trials, such as bioanalysis. With more than 4,000 attendees, 630 speakers, and 300 exhibitors, SCOPE 2026 reinforced its position as ...

This study focuses on emerging pharmacological and non-pharmacological strategies in the treatment of obesity, as well as evolving new paradigms for the future. It describes the contribution of incretin-based therapies, particularly GLP-1 receptor agonists and their multi-agonist counterparts, which provide robust effects on weight loss and metabol...

Over the last 3-5 years, growing cost pressure on healthcare and pharmaceutical companies and a significant shift towards outcome based healthcare approach have resulted in companies increasingly adopting real world data and evidence solutions to optimize their operation and cost using analytics. Earlier, applications of RWE were largely limited to...

The bio‑CDMO industry is entering an era of accelerated growth driven by the global shift toward complex biologics, including monoclonal antibodies, antibody-drug conjugates (ADCs), cell and gene therapies, recombinant proteins, and advanced vaccines. Large molecules are projected to record a 10.3% CAGR between 2025 and 2031, signaling sustained de...

09 May 2025  |  Global  |  Technology Research

Emerging Anti-aging strategies

Evolving Anti-aging Strategies Are Driving Transformational Growth in Innovation, Market Players, and Emerging Opportunities

Infographics

×

This report delves into the rapidly evolving anti-aging industry, highlighting the breakthrough innovations in cellular and genomic rejuvenation as well as AI/ML-driven anti-aging strategies. It explores the industry ecosystem, covering key players, emerging players, and academic researchers transforming the field. The analysis includes major techn...